Analogues nke ọgwụ linagliptin * (linagliptin *)

5 mg mbadamba ihe nkiri

Otu mbadamba ihe

ike - linagliptin 5 mg,

ndị na-ebu ụzọ: mannitol, stgelatinized starch, stachi ọka, copovidone, magnesium stearate,

Opadry shei®pink (02.)F34337): hypromellose 2910, titanium dioxide (E 171), talc, macrogol 6000, iron (III) oxide uhie (E 172).

Mpempe akwụkwọ gbara okirikiri nwere biconvex, nwere akụkụ gbara agba, kpuchie ya na fim nke agba uhie na-acha uhie uhie, nke etinyere ya na akara ngosi BI n'otu akụkụ ma kanye ya na "D5" n'akụkụ nke ọzọ.

Ngwongwo ogwu

Mlọ ọgwụ

Mgbe ịralụsịrị ọgwụ linagliptin na ọgwụ nke 5 mg, ọgwụ ahụ na-abanye ngwa ngwa, a na-enweta mkpo Plasma kachasị elu (Tianx median) mgbe awa 1.5 gachara. Plasma linagliptin na-ebelata dịka usoro atọ. Ogologo ndụ ọdụ ahụ dị ogologo (ihe karịrị otu narị awa), nke bụ nke kachasị n'ihi nkwụsi ike nke linagliptin na DPP-4 ma anaghị ebute mkpo ọgwụ ahụ. Ndụ ọkara na-arụ ọrụ maka nnakọta nke linagliptin mgbe nchịkwa nke linagliptin ugboro ugboro na kilogram 5 dị ihe dị ka awa iri na abụọ. Mgbe ị doseụ ọgwụ lignagliptin na otu 5 mg, ọgwụ plasma na-adịgide adịgide na-enweta ihe ọ bụla mgbe usoro nke atọ gasịrị, ebe AUC (mpaghara n'okpuru oge ịta ahụhụ) nke lignagliptin na plasma na-ebili ihe dịka 33% ma e jiri ya tụnyere nke mbụ. Ngwakọta nke mgbanwe dị iche iche na pọọm pharmacookinetic maka AUC nke linagliptin dị obere (12.6% na 28.5%).

The pharmacokinetics nke lignagliptin abụghị ndezi, ngụkọta plasma AUC nke lignagliptin na-abawanye obere-ịdabere karịa nke AUC na-enweghị ego, na-abawanye na nha. Aclọ ọgwụ ọgwụ nke linagliptin na ahụike na ndị ọrịa nwere ụdị ọrịa shuga mellitus 2 (ụdị nke abụọ).

Mwepu: kpam kpam bioavailability nke linagliptin bụ ihe dịka 30%. Ceptionnabata nke linagliptin na nri nwere nnukwu abụba na-abawanye oge ịbịaru Cmax ka awa abụọ ma na-eduga na mbelata Cmax site na 15%, mana ọ naghị emetụta awa AUC0-72.Ọ nweghị mgbanwe dị mkpa na Cmax na Tmax, ya mere, enwere ike iji linagliptin mee ihe n'agbanyeghị agbanye ya nri.

Nkesa: ngụda oke nke nkesa na ụzọ inye ihe ruru ọkara mgwo 5 na-abụ ihe dị ka 1110 lita, na-egosi oke nkesa akwara. Ihe jikọrọ linagliptin na protein plasma dabere na ị ofụ ọgwụ ahụ wee belata na 99% na 1 nmol / L ruo 75-89% na> 30 nmol / L, nke na-egosi saturation nke na-ejikọ ọnụ na DPP-4 na mmụba nke mkpokọta lignagliptin. N'ihe dị elu nke linagliptin na ngụkọta oge zuru ezu nke DPP-4, 70-80% nke linagliptin na-ejikọ na protein ndị ọzọ (ọ bụghị DPP-4), na 20-30% na plasma na steeti efu.

Metabolism na excretion: obere akụkụ nke ọgwụ inwetara na ahụ bụ metabolized. Routezọ kachasị nke ikuku na - abanye na eriri afọ bụ ihe dịka 80% yana 5% nke linagliptin dị na mmamịrị.

Mkpochapu ntaramahụhụ dị ihe dịka 70 ml / min.

Otu ndị ọrịa pụrụ iche

Ndị ọrịa nwere ọdịda akụrụngwa: n'ime ndị ọrịa nwere ogo ọdịda ọ bụla, achọghị ịgbanwe mmezi nke linagliptin. Obere nro nke ọdịda akụrụngaghị emetụtaghị ọgwụ ọgwụ nke linagliptin na ndị ọrịa nwere ọrịa shuga nke 2.

Ndị ọrịa nwere ọrịa imeju: N'ime ndị ọrịa nwere ọrịa imeju nke ogo ọ bụla (klas A, B na C dabere na nhazi nke nwatakịrị), ekwesighi imeghari dose nke linagliptin.

Ndozigharị ntụgharị nke dabere na okike, ihe ndekọ ahụ mmadụ (BMI), agbụrụ, na afọ ime anaghị achọ.

Umuaka: enweghi omumu nke pharmacokinetics nke linagliptin na umuaka.

Mlọ ọgwụ

Linagliptin bụ onye na - egbochi enzyme DPP-4 (dipeptidyl peptidase 4, EC koodu 3.4.14.5), nke a na - etinye aka na inactivation nke homonụ - glucagon-like peptide-1 (GLP-1) na glucose-based insulinotropic polypeptide (GIP). A na-ebibi homonụ ndị a ngwa ngwa site na DPP-4 nke enzyme. Abụọ na etinye aka na usoro physiological nke glucose homeostasis. Okpukpo ukwu nke mmiri nzuzo n’ehihie di ala, ọ na adi elu n’iru nri. GLP-1 na GIP na - akwalite biosynthesis na zoro ezo nke insulin site na mkpụrụ ndụ beta nke pancreatic na-eme ka ọkwa glucose ọbara dị elu ma dị elu. Na mgbakwunye, GLP-1 na-ebelata ihe nzuzo glucagon site na mkpụrụ ndụ alịp pancreatic, nke na-eduga n'ịbelata mmepụta glucose na imeju.

Linagliptin nwere ihe jikọrọ nke ọma na ijikọ ọnụ na DPP-4, nke na-eme ka mmụba na-aga n'ihu na oge ịchekwa ọrụ ha. Linagliptin na-eme ka mmịkọta insulin dabere na ọkwa glucose ma na-ebelata glucagon, na-eme ka glucose homeostasis dịkwuo mma.

Linagliptin na-ejikọta ya na DPP-4, n'imevitro nhọrọ ya karịrị nhọrọ maka DPP-8 ma ọ bụ ọrụ maka DPP-9 karịa ugboro 10,000.

Arụmọrụ arụmọrụ yana nchekwa

Iji tụọ arụmọrụ yana nchekwa ọfụma, ejiri 8 lintiliptin mee nyocha nke nyocha nke usoro III.

Linagliptin monotherapy: ojiji nke linagliptin na dose nke 5 mg otu ugboro n'ụbọchị mere ka mbelata nke ukwuu na glycated haemoglobin A (HbA1c) site na 0.69% ma e jiri ya tụnyere placebo, ndị ọrịa nwere ọkwa HbA1c nke dị 8%. Linagliptin na-ebute nnukwu mbelata glucose plasma na-ebu ọnụ (GPN) na awa 2 mgbe nri gasịrị (GLP). A na - ahụkarị ọrịa hypoglycemia n'ime ndị ọrịa na - anata linagliptin ma ọ bụ placebo.

Linagliptin monotherapyn'ime ndị ọrịa anaghị adabara ọgwụgwọ metformin n'ihi ntachi obi ya ma ọ bụ contraindications n'ihi ọdịda akụrụ, ọ gosipụtara mmụba dị elu na ọkwa HbA1c site na - 0,57% ma e jiri ya tụnyere placebo, ndị ọrịa nwere ọkwa HbA1c nke ihe dịka 8.09%. Linagliptin gosipụtara nnukwu mbelata glucose plasma glucose (GPN) ma e jiri ya tụnyere placebo. A na - ahụkarị ọrịa hypoglycemia n'ime ndị ọrịa na - anata linagliptin ma ọ bụ placebo.

Linagliptin monotherapy: data sitere na ntụnyere izu iri na abụọ na placebo na data sitere na izu iri abụọ na isii na ntụnyere α-glucosidase inhibitor (voglibose).

A mụkwara ịdị mma na nchekwa nke linagliptin monotherapy ma e jiri ya tụnyere placebo (izu 12 na-adịgide) yana voglibose (α-glucosidase inhibitor) maka izu iri abụọ na isii. Linagliptin na ọgwụ nke 5 mg dugara na mmụba dị elu na ọkwa HbA1c ma e jiri ya tụnyere placebo (-0.87%), nkezi ọkwa HbA1c bụ 8.0%. E gosiputara na ojiji nke linagliptin na onwa nke 5 mg ka amuma site na mmụba buru ibu na ọkwa HbA1c, mgbanwe -0.32% ma e jiri ya tụnyere voglibose, nkezi larịị nke HbA1c bụ 8.0%. Na mgbakwunye, linagliptin butere nnukwu ọganihu na glucose plasma na-ebu ọnụ (GPN) (mbelata nke 19.7 mg / dl / 1.1 mmol / L) ma e jiri ya tụnyere placebo na 6.9 mg / dl / 0.4 mmol / L atụnyere voglibose), yana ọkwa HbA1c

Nkọwapụta ọgwụ ọjọọ

Linagliptin * (Linagliptin *) - Nnukwu hypoglycemic. Linagliptin bụ ihe na - egbochi enzyme dipeptidyl peptidase-4 (DPP-4), nke a na - etinye aka na ntinye nke homonụ - ụdị peptide glucagon dị ka G1P (GLP-1) na glucose na - adabere glucose-polypeptide glucose (HIP). A na-ebibi homonụ ndị a ngwa ngwa site na DPP-4 nke enzyme. Abụọ ndị a metụtara na-ejigha ọkwa glucose physiological. Nchịkọta basal nke GLP-1 na GUI n'oge ụbọchị dị ala, ha na-abawanye ngwa ngwa na nzaghachi nri. GLP-1 na HIP na - akwalite insulin biosynthesis na nzuzo ya site na mkpụrụ ndụ beta nke pancreatic na -echekarị ma ọ bụ bulie ogo glucose n'ọbara. Na mgbakwunye, GLP-1 na-ebelata ihe nzuzo glucagon site na mkpụrụ ndụ alịp pancreatic, nke na-eduga n'ịbelata mmepụta glucose na imeju.

Linagliptin na-arụ ọrụ nke ọma na enzyme DPP-4 (njikọta na-agbanwe agbanwe), nke na-eme ka mmụba na-aga n'ihu na ntinye uche na ichekwa ogologo oge maka ọrụ ha. Ọ na - eme ka mmiri ọgwụ glucose dabere glucose na - agbada ma nwee mgbatị glucagon, nke na - eduga n'ịhazi ọkwa glucose ọbara. Linagliptin na-ejikọ ya na enzyme DPP-4 ma nwee nnukwu nhọrọ 10,000 karịa maka DPP-4 ma e jiri ya tụnyere enzymes dipeptyl peptidase-8 ma ọ bụ dipeptyl peptidase-9 na vitro.

Leasedị ntọhapụ, ihe mejupụtara na nkwakọ

Odikwa na mbadamba mbadamba n’ime uzo uzo abuo maka alogliptin - 12.5 na 25 mg.

Ndị pụrụ iche (dịka ọmụmaatụ, "Vipidia"):

• mannitol
• microcrystalline cellulose,
• Hyprolose
• sodium croscarmellose,
• stereta magnesium.

Mbadamba nkume ndị dị mma, nke a kwakọtara na blisters. N'ime ngwugwu 4 blisters nke 7 iberibe.

Omume ọgwụ

Ọrịa hypoglycemic. Ọ bụ ihe mgbochi nke DPP-4, nke na-emebi homonụ nke ibu ọrụ. Ha na-enyere aka iwelie mmepụta insulin site na mkpụrụ ndụ beta pancreatic, yana belata mmepụta glucose imeju. N'ihi ya, glycosylated haemoglobin na-agbadata ma tinye uche nke glucose n'ọbara na-ebelata, na afọ na-enweghị isi, yana mgbe ha richara nri.

Mlọ ọgwụ

Bioavailability fọrọ nke nta ka ọ bụrụ 100%. Enwere ike iji ya mee ihe n'agbanyeghị oge nri, n'ihi na nke a anaghị emetụta nnweta na ịmịkọrọ ọnụego nke ihe arụ ọrụ. A na-enweta ntinye uche kachasị mgbe awa 1-2 gachara. Ndi-auba ke ahu. Ọ bụ akụrụ na-agbanweghi agbanwe. Akụkụ akụkụ ahụ na-ewepu akụkụ ahụ. Ọkara ọkara nke anụ ahụ bụ elekere 21.

Ihe ngbanwe

• Hypersensitivity na mmiri,
• Siri ike gbasara akụrụ na ọrịa ịba ọcha n'anya,
• Ọrịa shuga 1dị 1
• Ọrịa mamịrị ketoacidosis
• A akụkọ ihe mere eme nke coma
• Obi ada mba
• Undermụaka n’agbata afọ 18
• Ime na lactation.

Jiri nlezianya jiri okwu ndị a:

• Ọrịa mgbu
• Ọkọlọtọ gbasara akụrụngwa ọdịda
• N'ikuku na njikọta ya na ndị nnọchite hypoglycemic ndị ọzọ.

Ntụziaka maka ojiji (usoro na usoro onunu ogwu)

A na -ewere ya ọnụ site n’enyeghị ata ahịhịa, mana ejiri mmiri dị ukwuu sachapụ ya. Nkwado izugbe bụ 25 mg nke alogliptin kwa ụbọchị. Ọ bụ dọkịta na-ahụ maka ịga nyere gị ọnụego ahụ dabere na akaebe. Enwere ike iji ya mee ihe na njikọta ọgwụ. N'okwu a, a na-ebelata usoro onunu ogwu iji zere hypoglycemia. Ọ bụrụ n’ịfughị ​​ọgwụ, ọ ga-adị mma ka ị theụọ ọgwụ ahụ ozugbo enwere ike. A machibidoro okpukpu abụọ iji nwude ya!

Mkparịta ụka ọgwụ ọjọọ

O nweghi otutu ihe choputara na mmekorita nke alogliptin na ihe ndi ozo.

Akụkụ ahụ n'onwe ya anaghị emetụta ọrụ nke ọgwụ ndị na-esonụ:

• kafiin
• glibenclamide,
• warfarin
• tolbutamide
• pioglitazone
• atorvastatin,
• ogwu gboro ya
• dextromethorphan
• fexofenadine,
• midazolam
• metformin
• digoxin
• cimetidine.

Achọpụtaghị mmetụta nke alogliptin:

• gemfibrozil
• cyclosporin
• fluconazole
• alfa glucosidase inhibitor
• ketoconazole,
• metformin
• pioglitazone
• digoxin
• cimetidine
• atorvastatin.

Nke ahụ bụ, nnabata ha abụọ adịghị mma. Agbanyeghị, ekwesiri icheta na mgbe ị na - agwọ ọrịa alogliptin ọnụ na sulfonylurea, insulin, ọ dị mkpa ịgbanwe mmezi iji belata ihe ize ndụ nke hypoglycemia.

Ntụziaka pụrụ iche

Ọ dị mkpa mgbe ị na-eji ọgwụ hypoglycemic ndị ọzọ ịhọrọ ọgwụ kwesịrị ekwesị iji zere nsonaazụ na-adịghị mma.

Ekwesịrị ịkpachara anya mgbe ị na-edepụta ọgwụ maka ndị nwere ọrịa ịba ọcha n'anya na akwara na agadi.

E nwere ihe ọghọm nke ịmalite ajọ ọrịa pancreatitis. Mgbaàmà ya bụ isi, mgbu dị n’afọ. Ihe ọ bụla na-enyo enyo banyere mmepe ya chọrọ ileba anya na ọgwụgwọ kwesịrị ekwesị.

Ọ bụrụ na ọghọm dị na arụ ọrụ akụrụ ma ọ bụ imeju n'oge ọgwụgwọ, aga - agbanwe usoro ọgwụgwọ ya ma kwụsịkwa ọgwụ ahụ.

Alogliptin naanị anaghị emetụta ikike ịkwọ ụgbọala, n'agbanyeghị, yana insulin ma ọ bụ sulfonylurea, ihe egwu a pụtara. Ya mere, ọ bụrụ na ọ ga-ekwe omume, ịgaghị ajụ ịnya ụgbọ ala ma jiri usoro rụọ ọrụ.

A na-ewepụta ya naanị na ndenye ọgwụ!

Jiri na nwata na nká

Enweghị data na nsonaazụ ahụ ụmụaka, yabụ, amachibidoro ọgwụ a maka ịgwọ ndị mmadụ na-erubeghị afọ 18.

Enweghị contraindications maka nnabata na ndị ọrịa agadi, agbanyeghị, ọ bara uru icheta na ndị ọgbọ a nọ n'ihe ize ndụ maka hypoglycemia na ketoacidosis. A choro ileba anya na onodu a.

Tụnyere ihe analogues

E nwere ọtụtụ ọgwụ nwere njiri mara otu. Ekwesịrị ịtụle ha maka iji ha tụnyere.

Vipidia. Mbadamba Alogliptin. Akwụ ụgwọ - site na ngwugwu 840 rubles. Takeda GmbH, Japan rụpụtara. Kacha nkịtị ngwaahịa na ihe a na ihe mejupụtara.

"Januvia." Ihe na-arụ ọrụ bụ sitagliptin. Ngwaahịa ọnụ, ọnụahịa - site na 1700 rubles. Emeputa - Merck Sharp na Dome, USA. Ngwongwo nke ogwu di nso ka o kwere mee n’elu. Enwere ụzọ atọ maka iji usoro onodu ogwu eme ihe. Contrafọdụ contraindications, nyocha dị mma.

"Yanumet." Ọnụ ego nke ngwugwu nke mbadamba 56 bụ 2800 rubles. Ngwakọta - metformin na sitagliptin na njikọ. Emebere ya na Merck Sharp & Dome, USA. A na-eji ya na monotherapy yana yana ọgwụ ndị ọzọ, gụnyere insulin. Ọtụtụ ihe mmeghachi omume na mgbochi na mbanye. Agbanyeghị, nyocha na-ekwu na ọ na-enyere aka belata ibu nke ọma, nke dị ezigbo mkpa maka ndị na-arịa ọrịa shuga.

Galvus Met. Ọnụahịa - site na 1500 rubles. Onye na - emepụta ihe - "Novartis", Switzerland. Ngwakọta ahụ gụnyere metformin na vildagliptin. Ọgwụ dị irè nke na - enyere aka ịbelata oke mgbe ị na - eri nri. Enwere ọtụtụ contraindications.

"Combogliz Prolong." Nwere metformin na saxagliptin. Ọnụahịa - 3300 rubles na n'elu. Na - arụpụta ụlọ ọrụ ahụ "Bristol-Myers Squibb", USA. Mbadamba ịtọhapụ. Enwere ọtụtụ mgbochi na mbanye. Jiri nlezianya na-emeso ndị agadi.

Bagomet. Ọgwụ dị ọnụ ala karịa (site na 160 rubles), mana ọ dị otu na ihe Njirimara. A na - emepụta ụlọ ọrụ "Chemistry Montpellier", Argentina. N'ihe dị ọnụ ala, ogo ahụ ka dị elu. Nyocha banyere ọgwụ ahụ dị mma. Ihe mejuputara metformin na glibenclamide.

Glibomet. Mbadamba nke Berlin Chemie, Germany rụrụ arụ. Ọnụahịa - site na 350 rubles. Ihe ndị na-arụ ọrụ bụ glibenclamide na metformin. Ọgwụ nwere ọtụtụ ihe amachibidoro ị takingụ mmanya, achọpụtara na o nweghị adabara ndị ọrịa shuga niile. Kwesịrị ekwesị maka ọgwụgwọ ngwakọta.

Mkpebi ịgbanwe na ọgwụ ọzọ bụ ọkachamara. Amachibidoro ị medicationụ onwe gị ọgwụ!

Ọtụtụ mgbe kwuru dị mma. Ndị mmadụ na-ahụ ezigbo nsonaa ma na monotherapy yana yana njikọta ọgwụgwọ. Achọghị ịdị arọ nke na-adịgide adịgide. Nsonaazụ ndị a na-adịghị ahụkebe.

Valentina: “Mama m arịa ọrịa shuga kemgbe afọ iri. Anwalela ihe niile ọgwụ niile, anyị achọghị ịnọdụ na insulin. Ugbu a ka edepụtara ya Glucophage Long na Vipidia. Anyị nwere obi uto na nsonaazụ ahụ. Ibu ibu belatara. Ahụ bịara dị ya mma, ọ gbasoro ike, ụkwụ ya anaghị agbacha agbacha na ọnya. Ọzọkwa, ọkwa shuga dịtebeghị aka. Nanị ọgwụ!

Denis: “Ejirila m Vipidia ihe karịrị afọ abụọ. Nke a bụ ọgwụ kachasị mma m nwara. Sugar kwụsiri ike, dịkwa ka ibu. Enweghị mmetụta ọ bụla. Na ihe kacha amasị m - agụụ nwere obere, achọghị m iri nri. ”

Larisa: “A na-agwọ m ọrịa mamịnara, mana o jighị m mma. Sugar wụliri elu. Dọkịta gwara m ka m gaa Vipidia. O kwuru na ọghọm ọghọm ya, na-arụ ọrụ ọfụma karịa m. O kwuru eziokwu. Sitena shuga dị larịị, ọkachasị ma ọ bụrụ na anaghị m emebi nri. Otu mbadamba ụbọchi zuru ezu maka ahụ ka ọ na-arụ ọrụ nke ọma. Ma nke kachasị mkpa - enweghị ụjọ dị otú ahụ na hypoglycemia pụtara. Isi ihe abughi imebi nri. Obi dị m ụtọ nke ukwuu. ”

Alla: “Ejirila m Vipidia dị ka ọgwụ bụ́ isi ruo afọ ole na ole. Anyị na dọkịta na-agbakwunye ọgwụ ọgwụ ndị ọzọ mgbe niile, dịka mkpa anụ ahụ na-agbanwe mgbe ụfọdụ. N’ime oge ime ime, ọ tụgharịrị insulin, mana mgbe ọ rịọsịrị ka enyeghachi ya Vipidia. Ọrịa ahụ lara n’iyi, bụ́ nke o jisiri ike nweta n’oge ahụ, ahụ ike ya ka mma. Na mkpokọta, ọgwụ a masịrị m. ”

Igor: “Ejiri m Vipidia na ọgwụgwọ. M ji nwayọọ nwayọọ chọpụta na ọgwụ ahụ adịghị m mma. Shuga agbanweghị, mgbe ahụ ọ nwedịrị njọ. Dọkịta kwuru na ọgwụ ezughị m oke. Ekwesịrị m ịgbanye insulin dị ka ihe na-egosi. ”

Ngwakọta na usoro onunu ogwu

Ọgwụ kachasị ewu ewu nwere linagliptin bụ ọgwụ otu aha.

Ngwakọta nke ọgwụ ahụ gụnyere isi ihe na - arụ ọrụ - linagliptin. Otu uzo ogwu a nwere 5 mg nke ihe eji eme ihe.

Na mgbakwunye na isi ihe na-arụ ọrụ, ọgwụ ahụ nwere ihe ndị ọzọ.

Ihe ndị ọzọ na ngwakọta nke ọgwụ ahụ bụ ndị a:

1. Mannitol
2. Egwu pregelatinized.
3. Ọka ọka.
4. Colovidone.
5. Stereta magnesium.

Ọgwụ bụ mbadamba ụrọ nwere ihe mkpuchi pụrụ iche.

Ngwakọta nke shells pụrụ iche nke mbadamba ihe ọ bụla gụnyere ihe ndị a:

• Opadra pink
• hypromellose,
• titanium dioxide
• ntụ ntụ talcum
• macrogol 6000,
• iron oxide di uhie.

Ọgwụ dị n'ụdị mbadamba ụrọ nwere ọdịdị gbara ya gharịị. Mbadamba nkume ndị ahụ emechila ọnụ ma kpuchie ihe nkiri. Mbadamba ụrọ mbadamba ya na-acha ọbara ọbara. Ejiri ihe ngosi ahụ na akara nke ụlọ ọrụ na-emepụta BI n'otu akụkụ yana D5 n'akụkụ nke ọzọ.

Mbadamba ụrọ dị na paịlị iri abụọ ọ bụla. A na-akwakọba blister na igbe kaadi. Otu ngwugwu ọ bụla nwere 3 blisters. Gbalịsie ike itinye ntuziaka maka iji ọgwụ ahụ na ngwungwu ọgwụ ọ bụla.

Ichekwa ọgwụ a ga-ebu ebe gbara ọchịchịrị na-adịghị elu karịa ogo 25 Celsius.

Ebe nchekwa ọgwụ agaghị adị ụmụaka. Ndụ nchekwa nke ọgwụ ahụ bụ afọ 3.

Mmechi

Ngwá ọrụ a nwere mmetụta kwụsiri ike ma na-adịgide adịgide n'ịgwọ ọrịa shuga. O nwere ezigbo nyocha n’etiti ndị ọrịa na ndị dọkịta. Nye ndị mmadụ ụdị ọrịa obere akụrụ na ọrịa imeju, nke na-achọkarị ka insulin gbanwee. Uru ndị ọzọ dị n’ị theụ ọgwụ ahụ bụ ikike pụtara ìhè ọ nwere ifelata ma melite ọdịmma niile. Ya mere, akụrụngwa ahụ na-ewere ọnọdụ ya n'etiti ọgwụ ndị ọzọ akwadoro.

Pharmacodynamics na pharmacokinetics nke ọgwụ

Mgbe nchịkwa ọnụ gachara ahụ, Linagliptin na-ejikọ aka ike dipeptidyl peptidase-4.

A na - atụgharịrị njikọta siri ike nke rụpụtara. Ijikọ enzyme na linagliptin na-eduga n'ịba ụba nke mkpokọta nke incretins n'ime ahụ ma na-enyere aka ịnọgide na-arụ ọrụ ha ruo ogologo oge.

Nsonaazụ nke ọgwụ ahụ bụ mbelata nke mmepụta glucagon na mmụba na nnweta insulin, nke n'aka nke ya na-ebute ịdị adị nke glucose na ahụ mmadụ.

Mgbe ị na-eji Linagliptin, mbelata glucose haemoglobin na mbelata nke ihe glucose na plasma ọbara na-akwụghachi ike.

Mgbe ị theụsịrị ọgwụ ahụ, ọ na-etinye obi gị dum ngwa ngwa. Oke ọgwụ a na plasma ruru 1.5 awa mgbe nchịkwa gasịrị.

Mbelata nke ọdịnaya nke linagliptin na-apụta na usoro abụọ. Iwepu ọkara ndụ dị ogologo ma na-eme ihe dịka 100 awa. Nke a bụ n'ihi eziokwu ahụ bụ na ọgwụ ahụ na-etolite ụlọ siri ike na enzyme DPP-4. N'ihi eziokwu na njikọta nke enzyme ahụ bụ mkpoghachi ọgwụ na ahụ adịghị eme.

N'ihe banyere iji Linagliptin na mkpokọta 5 mg kwa ụbọchị, a na-enweta ntinye uche nke otu ọgwụ na-arụ ọrụ n'ahụ ahụ onye ọrịa mgbe ọ 3ụsịrị obere ọgwụ 3.

Ezigbo bioavailability nke ọgwụ ahụ bụ 30%. Ọ bụrụ na ewere linagliptin n'otu oge ahụ nri nwere abụba bara ụba, mgbe ahụ nri dị otú ahụ anaghị emetụta oke oriri nke ọgwụ.

Dra wepụ ọgwụ ọjọọ n'ahụ ya na-abụkarị eriri afọ. Ihe dị ka pacenti ise na-apụtakarị site na sistemụ akụkụ akụrụ.

Ihe ngosi na contraindications maka iji ogwu

Ngosiputa maka iji linagliptin bu nnabata nke oria oria nke II n’aria oria.

N'oge ọgwụgwọ monotherapy, a na-eji linagliptin eme ihe na ndị ọrịa na-enweghị nchịkwa zuru oke nke glycemia n'ime ahụ site na nri na mmega ahụ.

A na-atụ aro iji ọgwụ ahụ eme ihe ma ọ bụrụ na onye ọrịa ahụ nwere nnwere onwe nke metformin ma ọ bụ ọ bụrụ na enwere contraindications maka ojiji nke metformin n'ihi mmepe nke ọdịda akụrụ na onye ọrịa.

A na-atụ aro ọgwụ a maka ọgwụgwọ abụọ mejupụtara yana ngwakọta na metformin, ọgwụ sulfonylurea ma ọ bụ thiazolidinedione, na mmemme ahụ na iji usoro ọgwụgwọ nri, mmega ahụ na monotherapy na ọgwụ egosipụtara adịghị arụ ọrụ.

Ọ bụ ihe ezi uche dị na iji Linagliptin dị ka ihe mejupụtara usoro ọgwụgwọ atọ, ma ọ bụrụ na nri, mmega ahụ, monotherapy ma ọ bụ ọgwụgwọ abụọ na - enyeghị nsonaazụ dị mma.

O kwere omume iji ọgwụ a jikọta ya na insulin, mgbe ị na-eme ọgwụgwọ n'ọtụtụ ọgwụ maka ọrịa shuga mellitus, na enweghị mmetụta nke iji nri mmega ahụ na ọgwụ insulin na-adịghị n'ọtụtụ ọgwụ

Ihe ndị ọzọ dị na contraindications maka iji ngwaahịa ọgwụ bụ:

• ọnụnọ n'ahụ ahụ onye ọrịa nke ụdị shuga mellitus 1,
• mmepe nke ketoacidosis mamịrị,
• ime na lactation,
• afọ onye ọrịa erughi afọ 18,
• ọnụnọ nke hypersensitivity na emereme ahụ ahụ nke akụkụ ọgwụ ọ bụla.

Amachibidoro Linagliptin iji ya n'oge mmechi na ara. Nke a bụ n'ihi eziokwu ahụ na - arụ ọrụ, mgbe ọ batara n'ọbara onye ọrịa, na - enwe ike ịgafe ihe mgbochi placental, ma nwee ike ịbanye na mmiri ara ara n'oge a na-enye nwa ara.

Ọ bụrụ na ọ dị ezigbo mkpa iji ọgwụ eme ihe n’oge a na-enye nwa ara, a ga-akwụsị inye ya ara ozugbo.

Ntuziaka maka iji ọgwụ ahụ

Ntụziaka maka ị ofụ ọgwụ ahụ na-egosi na a na-eji Linagliptin na ọgwụgwọ nke ụdị ọrịa shuga 2 ọrịa shuga na usoro nke 5 mg otu ugboro n'ụbọchị, nke bụ otu mbadamba. A na-ewere ọgwụ ọnụ.

Ọ bụrụ n’ịchụrụ oge ị theụ ọgwụ, ị kwesịrị ị were ya ozugbo onye ọrịa chetara nke a. Amachibidoro iji okpukpo abụọ nke ọgwụ ahụ.

Mgbe ị na-a theụ ọgwụ ahụ, dabere na njirimara nke mmadụ, ụfọdụ nsonaazụ nwere ike ime.

Nsonaazụ na-eme na ahụ onye ọrịa nwere ike imetụta:

1. Usoro ahụ ji alụso ọrịa ọgụ.
2. Akụkụ akụkụ akụkụ akụkụ iku ume.
3. Usoro ọnya afọ.

Na mgbakwunye, mmepe nke ọrịa na-efe efe na ahụ, dịka nasopharyngitis, ga-ekwe omume.

Mgbe ị na-eji Linagliptin na Metformin, nsonaazụ ndị a nwere ike ime:

• dị ka hypersensitivity,
• omume nke ụkwara
• mmepe nke pancreatitis
• Ọrịa nke ọrịa na-efe efe.

N'ihe banyere iji ọgwụ ahụ eme ihe na njikọta nke usoro ume ndụ sulfonylureas ọhụụ, ọ ga-ekwe omume ịzụlite na nsogbu anụ ahụ metụtara ịrụ ọrụ:

1. Usoro ahụ ji alụso ọrịa ọgụ.
2. Usoro nhazi.
3. Sistem.
4. Ahụ gastrointestinal.

N'ihe banyere iji Linagptin na Pioglipazone, enwere ike ịhụ mmepe nke nsogbu ndị a:

• dị ka hypersensitivity,
• hyperlipidemia na ọrịa shuga
• omume nke ụkwara
• ọria aru
• ọrịa na-efe efe
• I nweta ibu.

Mgbe ị na-eji Linagliptin na insulin n'oge ọgwụgwọ, mmetụta ndị ọzọ na-esote nwere ike ịmalite ahụ ahụ onye ọrịa:

1. Mmepe nke hypersensitivity n'ime ahụ.
2. Ọdịdị nke ụkwara na mgbakasị ahụ na sistem iku ume.
3. Site na usoro digestive, ọdịdị nke pancreatitis na afọ ntachi ga-ekwe omume.
4. Ọrịa nwere ike ibute.

N'ihe banyere iji Linagliptin nke ụdị nke abụọ maka ọrịa mellitus ọrịa shuga yana njikọta usoro Metformin na sulfonylurea, hypersensitivity, hypoglycemia, coughing, ihe ịrịba ama nke pancreatitis na uru dị arọ nwere ike ịmalite ahụ.

Na mgbakwunye na nsonaazụ ndị a, ọdịdị na mmepe nke angioedema, urticaria, nnukwu pancreatitis, ọnya anụ ahụ na ahụ onye ọrịa ga-ekwe omume.

Ọ bụrụ n ’ịdoụbiga mmanya ókè, a ga-eji ihe ndị a na-emekarị iji kwado anụ ahụ.

Measureskpụrụ ndị dị otú a bụ iwepụ ọgwụ ahụ n'ahụ ahụ na omume nke usoro ọgwụgwọ Symptomatic.

Nmekorita nke linagliptin na ogwu ndi ozo

Site na nhazi oge nke Metformin 850 na Linagliptin, mbelata nke ukwuu na ọkwa dị na ahụ onye ọrịa ahụ.

Aclọ ọgwụ ọgwụ mgbe ejiri ya na njikọta nke sulfonylurea nke ọgbọ ọhụụ enweghị ihe gbanwere.

Mgbe ejiri ya na usoro ọgwụgwọ siri ike nke thiazolidinediones, enweghị mgbanwe dị ukwuu na ọgwụ ọgwụ. Nke a na-egosi na linagliptin abụghị ihe na-egbochi CYP2C8.

Ojiji nke ritonavir na ọgwụgwọ siri ike anaghị eduga na mgbanwe mgbanwe dị ukwuu na ọgwụ ọgwụ na ọgwụ ọgwụ nke linagliptin.

Site na iji Linagliptin ugboro ugboro yana Rifampicin na-eduga n'ibelata oke ọrụ nke ọgwụ ahụ

A machiri Linagliptin n'ọrịa ụdị ọrịa shuga mellitus nke 1 ma ọ bụ ọgwụgwọ ketoacidosis nke ọrịa mamịrị.

Ugboro nke mmepe steeti hypoglycemia n'ahụ ahụ onye ọrịa n'oge monotherapy fọrọ nke nta.

Ohere inweta hyperglycemia na-abawanye ma ọ bụrụ na ejiri Linagliptin mee ihe na njikọta ọgwụ ndị bụ usoro nke sulfonylureas nke ọgbọ ọhụrụ. Maka nke a, ekwesịrị ilebara nlekọta pụrụ iche anya na usoro ọgwụgwọ siri ike.

Ọ bụrụ na ọ dị mkpa, ekwesịrị ịhazigharị ọgwụ ndị a ga-a toụ iji gbochie mmepe nke akara hypoglycemia.

Ojiji nke linagliptin emetụtaghị ọghọm nsogbu na ọrụ sistem.

Enwere ike iji Linagliptin na ọgwụgwọ ọrịa shuga na ndị ọrịa nwere nnukwu akụrụ.

Mgbe ị na-eji Linagliptin, a na-enwe mbelata dị ukwuu na ọdịnaya glycosylated haemoglobin na glucose na-ebu ọnụ.

N'ihe banyere enyo nke mmepe nke pancreatitis n'ime ahụ, a ga-akwụsị iji ọgwụ ahụ ozugbo.

Nyocha banyere ọgwụ ahụ, analogues ya na ọnụ ahịa ya

Ọgwụ ahụ, nke gụnyere linagliptin, nwere aha azụmaahịa mba ofesi Trazhenta.

Onye mepụtara ọgwụ ahụ bụ Beringer Ingelheim Roxane Inc., nke dị na United States. Na mgbakwunye, Ọstria na-emepụta ọgwụ ahụ. A na-enye ọgwụ ahụ site na ndị na-ere ọgwụ site na ndenye ọgwụ nke dọkịta na-ahụ maka ịga.

Nyocha ndị ọrịa gbasara ọgwụ a na-enwekarị echiche ziri ezi. Nyocha ndị na-ezighi ezi na-ejikarị ojiji nke ọgwụ ahụ yana imebi ntuziaka maka ojiji, nke na-akpata ịdoụbiga mmanya ókè ma ọ bụ ọdịdị nke mmetụta ndị ọzọ.

Ọnụ ego ọgwụ ahụ nwere uru dị iche dabere na ndị nrụpụta, marketer, na mpaghara ebe a na-ere ọgwụ ahụ na Russia.

Linagliptin 5 mg Nke 30 nke Beringer Ingelheim Roxane Inc. mepụtara, USA na Russia nwere ọnụ ahịa dị elu na mpaghara 1760 rubles.

Linagliptin na mbadamba 5 mg na ngwugwu nke iberibe iri atọ arụpụtara na Austria na Russian Federation nwere ọnụ ahịa dị ọnụ na nha site na 1648 ruo 1724 rubles.

Ihe analogues nke ogwu Trazhenta, nke nwere linagliptin, bu Januvia, Onglisa na Galvus. Ọgwụ ndị a nwere ọgwụ dị iche iche na-arụ ọrụ, mana mmetụta ha nwere n'ahụ ahụ yiri nke Trazhenta nwere n'ahụ ahụ.

Muta ihe banyere ogwu oria shuga na vidiyo na edemede a.